Sugi Predict

Sugi Predict / Compounds / SCHEMBL554516

SCHEMBL554516

SCHEMBL554516

O=S(=O)(c1ccccc1F)C(F)(F)F

nearest known ligand 0.45

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ HSD11B1 P28845 2/20 0.45
▸ SLC22A12 Q96S37 1/20 0.43
▸ CNR1 P21554 2/20 0.41
▸ NFE2L2 Q16236 4/20 0.40
▸ KAT6A Q92794 2/20 0.40
▸ AKR1B1 P15121 1/20 0.40
▸ KCNA5 P22460 1/20 0.40
▸ CA2 P00918 1/20 0.39
▸ CNR2 P34972 1/20 0.39
▸ ABCC9 O60706 1/20 0.39
▸ ABCC8 Q09428 1/20 0.39
▸ KCNJ11 Q14654 1/20 0.39
▸ KCNJ8 Q15842 1/20 0.39
▸ KMT2A Q03164 1/20 0.39
▸ L3MBTL1 Q9Y468 1/20 0.39
▸ ALDH1A1 P00352 1/20 0.39
▸ EPAS1 Q99814 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31504077 1.00 HSD11B1 (0.45) HSD11B1SLC22A12CNR1NFE2L2KAT6A
SCHEMBL13518318 0.90 HSD11B1 (0.40) HSD11B1SLC22A12CNR1NFE2L2KAT6A
SCHEMBL6929900 0.85 CA2 (0.44) HSD11B1SLC22A12CA2KMT2AALDH1A1
SCHEMBL1957830 0.83 HSD11B1 (0.46) HSD11B1SLC22A12CNR1NFE2L2KAT6A
SCHEMBL12666580 0.82 HSD11B1 (0.45) HSD11B1SLC22A12NFE2L2KAT6AAKR1B1
SCHEMBL7935370 0.80 HSD11B1 (0.40) HSD11B1SLC22A12NFE2L2KAT6AAKR1B1
SCHEMBL6264610 0.77 CA2 (0.43) CA2ABCC9ABCC8KCNJ11KCNJ8
SCHEMBL6000341 0.77 CA2 (0.39) HSD11B1SLC22A12CA2KMT2AALDH1A1
SCHEMBL945367 0.77 MEN1 (0.40) HSD11B1SLC22A12CA2KMT2AALDH1A1
SCHEMBL15916788 0.76 CA2 (0.56) HSD11B1AKR1B1CA2KMT2AL3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 104 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2307393-B1 A PROCESS FOR THE PREPARATION OF THE APOPTOSIS PROMOTER ABT-263 ABBOTT LAB (US) 2013-04-10 — — EP claimed
US-8168784-B2 Processes to make apoptosis promoters ABBOTT LABORATORIES (US) 2012-05-01 — — US claimed
JP-2011525182-A — — 2011-09-15 — — JP claimed
EP-2307393-A1 A PROCESS FOR THE PREPARATION OF THE APOPTOSIS PROMOTER ABT-263 Abbott Laboratories (US) 2011-04-13 — — EP claimed
US-20100317625-A1 NOVEL SULFONAMIDOMETHYLPHOSPHONATE INHIBITORS OF BETA-LACTAMASE 92229129 QUEBEC INC. (CA) 2010-12-16 — — US claimed
US-20090318689-A1 Processes To Make Apoptosis Promoters ABBOTT LABORATORIES (US) 2009-12-24 — — US claimed
WO-2009155386-A1 A PROCESS FOR THE PREPARATION OF THE APOPTOSIS PROMOTER ABT-263 ABBOTT LABORATORIES (US) 2009-12-23 — — WO claimed
CN-119823009-A Preparation method of 1-fluoro-2-trifluoromethanesulfonyl benzene 上海珂华生物科技有限公司 2025-04-15 — — CN disclosed
WO-2024026424-A1 QUINAZOLINONE DERIVATIVES AS AND RELATED USES BLACK DIAMOND THERAPEUTICS, INC. (US) 2024-02-01 — — WO disclosed
US-11370807-B2 Process for preparing sulfonamide compounds ASCENTAGE PHARMA (SUZHOU) CO., LTD. (CN) 2022-06-28 — — US disclosed
US-20220009952-A1 PROCESS FOR PREPARING SULFONAMIDE COMPOUNDS ASCENTAGE PHARMA GROUP CORP LIMITED (CN) 2022-01-13 — — US disclosed
CN-109641897-B Bcl-2 selective inhibitors, their preparation and use 北京赛林泰医药技术有限公司 2021-12-07 — — CN disclosed
US-11111259-B2 Acylsulfonamide derivatives for treating senescence-associated diseases and disorders UNITY BIOTECHNOLOGY, INC. (US) 2021-09-07 — — US disclosed
WO-2009155386-A1 A PROCESS FOR THE PREPARATION OF THE APOPTOSIS PROMOTER ABT-263 ABBOTT LABORATORIES (US) 2009-12-23 — — WO disclosed
EP-2049200-A2 NOVEL INHIBITORS OF BETA-LACTAMASE MethylGene Inc. (CA) 2009-04-22 — — EP disclosed
EP-2024376-A1 NOVEL SULFONAMIDOMETHYLPHOSPHONATE INHIBITORS OF BETA-LACTAMASE Merck & Co., Inc. (US) 2009-02-18 — — EP disclosed
WO-2008073142-A2 NOVEL INHIBITORS OF BETA-LACTAMASE MERCK & CO., INC. (US) 2008-06-19 — — WO disclosed
WO-2007139729-A1 NOVEL SULFONAMIDOMETHYLPHOSPHONATE INHIBITORS OF BETA-LACTAMASE MERCK & CO., INC. (US) 2007-12-06 — — WO disclosed
US-6242654-B1 REACTING A PHENOLATE COMPOUND WITH AN ORGANIC FLUORINATING AGENT TO PREPARE A FLUORINE SUBSTITUTED AROMATIC COMPOUND MITSUI CHEMICALS, INC. (JP) 2001-06-05 — — US disclosed
EP-1013629-A1 Preparation process of fluorine subsituted aromatic compound Mitsui Chemicals, Inc. (JP) 2000-06-28 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100317625-A1 NOVEL SULFONAMIDOMETHYLPHOSPHONATE INHIBITORS OF BETA-LACTAMASE MGAM, BPGM, PPME1 HSD11B1 2006/4885SLC22A12 2766/4885CNR1 4637/4885
US-20090318689-A1 Processes To Make Apoptosis Promoters BAX, BCL2, CCAR2 HSD11B1 2337/4885SLC22A12 3596/4885CNR1 4627/4885
US-11370807-B2 Process for preparing sulfonamide compounds BCL2, BCL3, BAX HSD11B1 4116/4885SLC22A12 3847/4885CNR1 2403/4885
US-20220009952-A1 PROCESS FOR PREPARING SULFONAMIDE COMPOUNDS BCL2, BCL3, BAX HSD11B1 4116/4885SLC22A12 3847/4885CNR1 2403/4885
US-11111259-B2 Acylsulfonamide derivatives for treating senescence-associated diseases and disorders ACAT1, ARSA, GLA HSD11B1 396/4885SLC22A12 614/4885CNR1 3709/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.